How do synthetic cannabinoids compare to naturally occurring ones??
This week we’re joined by pharmacologist Dr Saoirse O’Sullivan and pharmacist Dr Andy Yates, experienced cannabis scientists and advisors to Artelo Biosciences.
In this episode we take an in-depth look into cannabinoids, exploring the three classes – endocannabinoids, phytocannabinoids and synthetic cannabinoids in detail, alongside the uses, benefits and limitations of each type.
→ View full show notes, summary, and access resources here:
About Dr Saoirse O’Sullivan, Ph.D
Professor Saoirse Elizabeth O’Sullivan received her doctorate from Trinity College Dublin in 2001 and moved to the University of Nottingham in 2002 as a Research fellow where she began researching cannabinoid pharmacology through basic and clinical research. She was made Lecturer in 2007, Associate Professor in 2011 and Full Professor in 2019. She has nearly 50 peer-reviewed articles and 3 books chapters on the topic of cannabinoid pharmacology dating back to 2004. Her specific interests are on the therapeutic potential of cannabis-based medicines in cardiovascular disease, stroke, cancer, diabetes, and inflammatory bowel disease. Her research methodologies span from cellular and animal models, to human healthy volunteer studies, systematic reviews and early phase clinical trials. In 2016, she was named the International Cannabinoid Research Society Young Investigator of the Year. In 2017, Saoirse set up an independent consulting company called CanPharmaConsulting Ltd, and through this, acts as scientific advisor to companies like Artelo Biosciences, CBDScience Group, Therapix Biosciences and Dragonfly Biosciences, helping to turn cannabinoid science into new medicines. She also develops educational tools around the use of cannabis-based medicines for higher learning institutes. She is a long-standing member of, and general secretary to, the International Cannabinoid Research Society. She works with charities, patient groups, healthcare professionals to educate on the benefits of cannabis-based medicines. Saoirse has worked with the BBC and is an expert witness for the police.
About Dr. Andy Yates, Ph.D
Dr. Andy Yates has more than 15 years experience in the pharmaceutical industry including 10 years as an executive at AstraZeneca. He held key roles within the medical affairs, commercial, business development and strategy functions for AstraZeneca’s in-line and development portfolio. Dr Yates has been extensively involved in the life-cycle management of key multi-billion dollar products leading to the funding and initiation of significant development programmes. Whilst in business development he led evaluations and transactions that resulted in multiple collaborative agreements with academia, biotechnology and peer pharma. Dr. Yates is a UK registered pharmacist who received his PhD in cannabinoid medicinal chemistry from the University of Nottingham.
When I started in 2002, I thought it was complex, so I can’t imagine what it’s like for somebody coming into this area now, it is so complex. Cannabinoids work on so many different targets in our body. 06:00
‘There will always be a group of people within the cannabis community who view synthetics as bad’ 36:20
Follow Saoirse on LinkedIn: https://www.linkedin.com/in/professor-saoirse-o-sullivan-98b6bb53/
Follow Andy on LinkedIn: https://www.linkedin.com/in/andy-yates-4985aa1/
Follow Artelo Biosciences Twitter: https://twitter.com/ArteloBio
Artelo Biosciences Website: https://artelobio.com/